Rigel Pharmaceuticals (RIGL) Key Ratios
$48.50
As on 03-Sep-2026 16:01EDT
Market cap
$868 Mln
Revenue (TTM)
$277 Mln
P/E Ratio
2.8
P/B Ratio
2.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 33.81 | -22.60 | 3.31 | 29.77 | 13.94 |
| EBIT | 86.13 | -60.61 | -14.50 | 68.55 | 91.67 |
| Net Profit | 99.79 | -71.00 | 229.08 | 118.08 | 112.80 |
| EPS | 100.98 | -73.08 | 214.18 | 114.00 | 101.44 |
| Book Value | -- | -- | 11,266.61 | -- | 59.50 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 14.32 | -2.20 | 33.02 | 43.89 | 14.66 |
| Net Margin
| -- | -30.22 | 116.30 | -- | -- |
| Return on equity
| 55.59 | -117.58 | 78.81 | 185.94 | -137.92 |
| Return on Capital
| 32.47 | -12.23 | -- | 144.49 | 36.74 |
| Return on Assets
| 33.61 | 9.82 | 70.75 | 108.34 | 12.44 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.14 | 18.24 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
144.49
|
36.74
|
-83.82
|
-131.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
78.81
Higher than Peers by 119.21
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
78.81
|
185.94
|
-137.92
|
118.75
|
-699.05
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
70.75
Higher than Peers by 101.73
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
70.75
|
108.34
|
12.44
|
-19.95
|
-38.84
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
33.02
Higher than Peers by 116.63
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
33.02
|
43.89
|
14.66
|
-15.59
|
-45.63
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
116.30
Higher than Peers by 208.97
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
116.30
|
124.72
|
9.75
|
-21.47
|
-48.44
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
3.31
Lower than Peers by 50.64
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
3.31
|
0.64
|
0.53
|
-0.03
|
-0.19
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-14.50
Lower than Peers by 13.70
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
-14.50
|
391.35
|
244.27
|
66.79
|
-340.73
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
229.08
Higher than Peers by 236.38
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
229.08
|
1,999.08
|
169.69
|
57.16
|
-226.97
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
214.18
Higher than Peers by 199.53
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
214.18
|
19.04
|
1.68
|
0.58
|
-2.24
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
381.87
Higher than Peers by 392.05
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
381.87
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
0.14
|
18.24
|
-2.11
|
-3.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.09
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
0.09
|
0.08
|
2.30
|
-0.28
|
-0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.95
Lower than Peers by 3.86
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
1.95
|
2.42
|
2.13
|
1.86
|
1.78
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.79
Lower than Peers by 3.90
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
1.79
|
2.30
|
2.04
|
1.76
|
1.64
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
15.74
Higher than Peers by 17.83
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
15.74
|
17.64
|
3.32
|
-2.65
|
-14.80
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
20.25
Higher than Peers by 1.11
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
20.25
|
17.59
|
23.21
|
26.14
|
33.53
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.61
Higher than Peers by 0.54
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
0.61
|
0.87
|
1.28
|
0.93
|
0.80
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
57.95
|
73.51
|
110.73
|
84.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
162.96
|
112.86
|
376.04
|
1,642.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
98.01
|
102.65
|
761.58
|
2,746.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
122.90
|
83.73
|
-274.81
|
-1,018.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
2.77
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
2.77
|
2.20
|
17.30
|
-1.01
|
-0.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.06
Lower than Peers by 3.13
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
2.06
|
2.06
|
92.01
|
-0.88
|
-1.90
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
8.71
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
8.71
|
5.36
|
10.00
|
-1.70
|
-0.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
868
Higher than Peers by 722
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rigel Pharmaceuticals (RIGL)
|
868
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|